Skip to content

A study on the precise prevention and treatment of perinatal pulmonary embolism based on genetic testing: a prospective study

A study on the precise prevention and treatment of perinatal pulmonary embolism based on genetic testing: a prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063325
Enrollment
Unknown
Registered
2022-09-04
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Interventions

loading dose group:initial 2-3 day's loading dose of warfarin combined with iW-PC dose prediction model

Sponsors

Shanghai Sixth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. No thrombotic disease before pregnancy; 2. Aged >18 years; 3. Pulmonary embolism was diagnosed by CTA; 4. The patient has never used warfarin and agrees to use warfarin this time; 5. No anticoagulant contraindications; 6. The patient is capable of attending scheduled follow-up visits; 7. The patient and her family members signed an informed consent.

Exclusion criteria

Exclusion criteria: 1. A history of stroke; 2. A history of warfarin allergy; 3. Persons with mental disorders; 4. Severe liver and kidney diseases; 5. Heparin induced thrombocytopenia; 6. International standard ratio of prothrombin time (INR)=1.4; 7. platelet count <100 x 10^9/L before treatment.

Design outcomes

Primary

MeasureTime frame
the time of reaching the expected level of INR;

Countries

China

Contacts

Public ContactWeifeng Huang

Shanghai Sixth People's Hospital

breeze-huang@hotmail.com+86 18930173670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026